Ann: SubB2M/CA15.3 Clinical Validation Data Investor Presentation, page-31

Agree Chartrader it’s not going to attract to much institutional interest / mandates until solidly + $100million
I don’t think that’s a problem at this stage given some of the bigger privateers they have on the register like Merchant and Moggs who have been big supporters (and probably why I am in the stock, they have been kind to me in other stocks they are in) .
For me the challenge they face is creating enough liquidity in the stock and seeking out more Merchant, Moggs type people to come in and bring their followers and of course continuing to deliver great research results and repeating regular properly targeted communication like this time.
I think eventually we have turned the corner, very impressed with the new CSO and the changes in people might finally be starting to make a difference.
Will be nice to see consistency in meeting milestones and commercial targets.
Our faith and patience might finally be rewarded.